Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ754805B2 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator - Google Patents
[go: Go Back, main page]

NZ754805B2 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator - Google Patents

Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Download PDF

Info

Publication number
NZ754805B2
NZ754805B2 NZ754805A NZ75480517A NZ754805B2 NZ 754805 B2 NZ754805 B2 NZ 754805B2 NZ 754805 A NZ754805 A NZ 754805A NZ 75480517 A NZ75480517 A NZ 75480517A NZ 754805 B2 NZ754805 B2 NZ 754805B2
Authority
NZ
New Zealand
Prior art keywords
compound
cystic fibrosis
modulator
pharmaceutical composition
medicament
Prior art date
Application number
NZ754805A
Other versions
NZ754805A (en
Inventor
Alexander Russell Abela
Timothy Alcacio
Corey Anderson
Paul Timothy Angell
Minson Baek
Jeremy J Clemens
Thomas Cleveland
Lori Ann Ferris
Peter Diederik Jan Grootenhuis
Raymond Stanley Gross
Original Assignee
Vertex Pharmaceuticals Incorporated
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to NZ795112A priority Critical patent/NZ795112A/en
Priority claimed from PCT/US2017/065425 external-priority patent/WO2018107100A1/en
Publication of NZ754805A publication Critical patent/NZ754805A/en
Publication of NZ754805B2 publication Critical patent/NZ754805B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Abstract

Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Claims (21)

1. A compound selected from Compound 1: (Compound 1), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing.
2. A compound selected from the following formula: a pharmaceutically acceptable salt thereof, and a deuterated derivative of any of the foregoing.
3. A compound of the following formula: (Compound 1).
4. A pharmaceutical composition comprising: (a) a compound of the following formula: (Compound 1) (b) a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 further comprising Compound II:
6. The pharmaceutical composition of claim 4 further comprising Compound III:
7. The pharmaceutical composition of claim 5 further comprising Compound III:
8. Use of a compound of the following formula: (Compound 1) in the manufacture of a medicament for treating cystic fibrosis.
9. Use of: (a) a compound of the following formula: (Compound 1) (b) a pharmaceutically acceptable carrier in the manufacture of a medicament for treating cystic fibrosis.
10. A pharmaceutically acceptable salt of Compound 1: (Compound 1).
11. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable salt of Compound 1: (Compound 1) (b) a pharmaceutically acceptable carrier.
12. The pharmaceutical composition of claim 11, further comprising Compound II:
13. The pharmaceutical composition of claim 11, further comprising Compound III:
14. The pharmaceutical composition of claim 12, further comprising Compound III:
15. Use of a pharmaceutically acceptable salt of Compound 1: (Compound 1) in the manufacture of a medicament for treating cystic fibrosis.
16. Use of a pharmaceutical composition of claim 12 in the manufacture of a medicament for treating cystic fibrosis.
17. Use of a pharmaceutical composition of claim 13 in the manufacture of a medicament for treating cystic fibrosis.
18. Use of a pharmaceutical composition of claim 14 in the manufacture of a medicament for treating cystic fibrosis.
19. Use of a pharmaceutical composition of claim 5 in the manufacture of a medicament for treating cystic fibrosis.
20. Use of a pharmaceutical composition of claim 6 in the manufacture of a medicament for treating cystic fibrosis.
21. Use of a pharmaceutical composition of claim 7 in the manufacture of a medicament for treating cystic fibrosis.
NZ754805A 2016-12-09 2017-12-08 Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator NZ754805B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ795112A NZ795112A (en) 2016-12-09 2017-12-08 Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662432537P 2016-12-09 2016-12-09
PCT/US2017/065425 WO2018107100A1 (en) 2016-12-09 2017-12-08 Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Publications (2)

Publication Number Publication Date
NZ754805A NZ754805A (en) 2023-11-24
NZ754805B2 true NZ754805B2 (en) 2024-02-27

Family

ID=

Similar Documents

Publication Publication Date Title
ZA202206810B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018064632A8 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
ZA202307129B (en) Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
MX2021000887A (en) Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer.
ZA202201794B (en) Crystalline forms of cftr modulators
AU2018351533A8 (en) Crystalline forms and compositions of CFTR modulators
EP4484440A3 (en) Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
MX2022004450A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases.
WO2018218070A3 (en) Covalent inhibitors of kras
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
MX2022004451A (en) HETEROARYL-BIPHENYL-AMIDES FOR THE TREATMENT OF DISEASES RELATED TO THE PD-L1 LIGAND.
MX418519B (en) Jak1 selective inhibitors
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
MX2024003738A (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds.
AU2018251118A8 (en) Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof
CR20210181A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MX2021007247A (en) Rapamycin derivatives.
MX2020008498A (en) Derivatives of sobetirome.
PH12021552513A1 (en) Pyrrole compounds
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
SG11201907945YA (en) Azetidine derivative
MX2021004379A (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections